Target Discovery to Candidate Selection and Beyond
Supporting stand-alone and integrated projects
Comprehensive platform from target ID to drug candidates
Target Identification and Validation
Finding druggable targets
Comprehensive coverage of target classes and therapeutic modalities
Hit Identification
Screening services to accelerate drug discovery
Integrated platform with diverse methods to identify hit compounds
Hit Validation and Early Optimization
Confirming chemistry tractability
In vitro screening platform to support medicinal chemistry
Lead Discovery Services
Enhancing the most promising compounds
In vivo services to accelerate drug discovery
Preclinical Drug Development
Enabling the selection of the best candidates
Integrated platform for preclinical R&D to accelerate timelines
Investigational New Drug Discovery
Comprehensive IND enabling testing platform
Supporting clients from research to market
Latest Science
Identification of Tofacitinib, Filgotinib and Ruxolitinib on experimental Sjögren’s syndrome...
Sjögren’s syndrome, which is affected hundreds of millions of people worldwide, is a chronic autoimmune disorder characterized by leukocytic infiltration...
LEARN MORE >Brain metastasis mouse models for the evaluation of multikinase inhibitors...
Lung cancer is the leading cause of cancer-related death worldwide. Nearly 80% of lung cancers are non-small cell lung cancer...
LEARN MORE >Brain metastasis mouse models for the evaluation of multikinase inhibitors...
Lung cancer is the leading cause of cancer-related death worldwide. Nearly 80% of lung cancers are non-small cell lung cancer...
LEARN MORE >Intra-carotid artery brain metastasis models for the evaluation of lung...
Non-CNS metastatic brain cancer is about 10 times more common than CNS cancer. Lung cancer and breast cancer account for...
LEARN MORE >Developing drug-induced resistant tumor models for efficacy evaluation of next-generation...
The therapeutic landscape of cancer has been transformed over the last few decades. Our understanding of cancer and its therapeutic...
LEARN MORE >Developing a panel of orthotopic syngeneic tumor models for IO...
Immuno-oncology (IO) therapy is the focus of drug discovery in recent years. Unlike chemotherapy or targeted agents, the pharmacological efficacy...
LEARN MORE >Development of an integrated in vitro and in vivo OVA-specific...
As the development of cancer immunotherapy and urgent demand of precision medicine, cancer vaccines have been envisioned as a novel...
LEARN MORE >Mouse hind limb tumor metastatic model to evaluate prophylaxis and...
Bone metastasis is one organ specific metastasis that cause severe pain and immobility, also increase mortality, lots of prophylaxis and...
LEARN MORE >Establishment of spatial transcriptomics assay to find the mechanism of...
Intra-tumor heterogeneity is one of the biggest challenges in cancer treatment today, not only on cell types and functions, but...
LEARN MORE >Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of...
Ionizing radiation has largely been recognized as a local targeted therapy by a variety of mechanisms, including inducing direct DNA...
LEARN MORE >Tumor evolution selectively inactivates the core microRNA machinery for immune...
Cancer cells acquire genetic heterogeneity to escape from immune surveillance during tumor evolution, but a systematic approach to distinguish driver...
LEARN MORE >DNA-encoded chemical libraries
The pharmaceutical industry relies upon a toolbox of methods to discover novel small molecules capable of modulating biologically relevant targets,...
LEARN MORE >Meeting Neurodegenerative Disease Head-On with Emerging Drug Discovery Strategies
Central nervous system (CNS) diseases represent a significant disease burden and are one of the leading causes of death and...
LEARN MORE >Evaluation of the efficacy of ADC in vitro and in...
Antibody drug conjugate (ADC) is a promising complex with therapeutic potential that aimed to the treatment of solid tumor and...
LEARN MORE >The critical platforms of PROTAC validation
In recent years, proteolysis targeting chimeric (PROTAC) technology has become an effective endogenous protein degradation tool in drug discovery. As...
LEARN MORE >Protein Degradation: Shifting the Paradigm of Resistance and Undruggables for...
With a recent $120 million IPO, a $55 million Series C, and a Pfizer R&D deal potentially worth $830 million,...
LEARN MORE >Empowering Organic Syntheses with Quantum Mechanics Analyses
Syntheses of specifically functionalized molecules continue to be rate limiting steps (RLS) in drug discovery. Improvement in this RLS means...
LEARN MORE >The Synthesis of an Entrepreneur: Merging a Passion for Biochemistry,...
Synthetic chemist Joseph Ready believes a huge amount of innovation in the drug industry comes from academia. Academic science is...
LEARN MORE >Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond
As a self-proclaimed drug hunter, Phil Jones is on a mission to identify the next generation of cancer medicines that...
LEARN MORE >Faster with high-speed fragment screening — Accelerate your drug discovery...
In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited...
LEARN MORE >Enabling Technology for Targeted Protein Degradation
Traditional small molecule therapeutic mechanisms have recently been augmented by a new strategy to specifically manipulate the levels of disease-related...
LEARN MORE >CRISPR Library Screen: A Powerful Tool For Identifying Novel Tumor...
Cancer is a genetic disease. Over time, somatic mutations accumulate and drive the proliferation of tumor cells. Knowledge of that...
LEARN MORE >Bifunctional Molecules: A Diverse New Modality That Unlocks New Target...
Bifunctional molecules are opening up once-inaccessible targets and enabling development of drugs that are less susceptible to target protein mutations....
LEARN MORE >How Diversity In Therapeutic Strategies Is Expanding The Drug Discovery...
For decades, researchers were largely reliant on small molecules to treat disease, leaving them unable to act on vast swathes...
LEARN MORE >Outsourcing Drug Discovery and Development: Considerations For Emerging Biopharma Companies
The pharmaceutical industry has become increasingly dependent on outsourcing as a means of driving both discovery and development pipelines. As...
LEARN MORE >